Ketamine is not an upper. It is classified as a dissociative anesthetic, a category distinct from both stimulants (uppers) and traditional depressants (downers). The confusion is understandable, though, because ketamine does some things that look stimulant-like on the surface, particularly raising heart rate and blood pressure, while its deeper effects on the brain are nothing like what amphetamines or cocaine do.
Why Ketamine Gets Confused With a Stimulant
The main reason people wonder whether ketamine is an upper is its effect on the cardiovascular system. Unlike most anesthetics, ketamine increases sympathetic nervous system activity, the same “fight or flight” system that stimulants activate. This means it can raise blood pressure, heart rate, and cardiac output. In one study of adults receiving ketamine for procedural sedation, 71% experienced a significant change in vital signs (defined as 20% or more above baseline) at some point during the procedure. That kind of cardiovascular bump is more commonly associated with stimulants than with sedatives.
Ketamine can also produce feelings of euphoria and heightened sensory experiences, which overlap with what people expect from uppers. Users report a wide range of effects including both pleasurable and intensely disorienting experiences. At lower doses, some people feel energized or mentally “lifted,” which adds to the stimulant impression.
How Ketamine Actually Works in the Brain
Stimulants like amphetamines and cocaine work by flooding the brain with dopamine, norepinephrine, and serotonin, the monoamine neurotransmitters responsible for alertness, pleasure, and motivation. Ketamine operates through an entirely different system. It blocks a receptor called the NMDA receptor, which is part of the glutamate signaling pathway. Glutamate is the brain’s primary excitatory neurotransmitter, far more fundamental than the monoamines that stimulants target.
By blocking NMDA receptors, ketamine triggers a brief surge of glutamate in certain brain regions within about 30 minutes of administration. This surge appears to promote new connections between brain cells, which is one reason ketamine has shown rapid antidepressant effects. But this mechanism is fundamentally different from the dopamine rush of a stimulant. Ketamine also affects norepinephrine, serotonin, and acetylcholine to varying degrees, which contributes to its complex and hard-to-categorize profile.
What the Experience Actually Feels Like
The subjective effects of ketamine depend heavily on dose, and they bear little resemblance to a stimulant high at any level. At sub-anesthetic doses (roughly 0.1 to 0.3 mg/kg given intravenously), ketamine produces mild pain relief with minimal changes to consciousness. People may feel relaxed, slightly detached, or mildly euphoric. The effects of a single dose at this level wear off in about 30 to 45 minutes.
At higher, anesthetic-level doses (1.0 mg/kg or above), ketamine produces a full dissociative state. People feel profoundly detached from their body and surroundings, may experience vivid hallucinations, and often have no memory of the experience afterward. At the extreme end, recreational users describe what’s called a “k-hole,” a state of near-complete sensory disconnection. None of this resembles the focused energy, confidence, and wakefulness of a stimulant. If anything, the high-dose experience has more in common with a powerful hallucinogen.
The DEA describes the dissociative effect simply: it makes people feel detached from their pain and environment. Ketamine also induces sedation, immobility, and amnesia, all the opposite of what an upper does.
Its Official Classification
Pharmacologically, ketamine is classified as a nonbarbiturate dissociative anesthetic. The DEA categorizes it as a Schedule III controlled substance, a tier that includes drugs with moderate potential for dependence. It was first approved in the United States in 1970 as an anesthetic.
Notably, ketamine doesn’t fit neatly on the standard sedation scale either. Medical guidelines have acknowledged that the dissociative state ketamine produces is inconsistent with the usual definitions of moderate or deep sedation. It exists in its own lane: not a classic sedative, not a stimulant, not a standard hallucinogen, but a drug that borrows features from several categories without belonging fully to any of them. It is, however, associated with cardiovascular and respiratory stimulation, which is why the “upper” label sticks in casual conversation even though it’s inaccurate.
Medical Uses Today
Ketamine’s unique mechanism has given it a second life beyond anesthesia. A nasal spray form called esketamine (a close chemical relative) is FDA-approved for treatment-resistant depression and for depressive symptoms in adults experiencing acute suicidal ideation. Its ability to produce antidepressant effects within hours, rather than the weeks or months required by traditional antidepressants, made it a significant development in psychiatry.
Because of its risks, including sedation, dissociation, respiratory depression, and potential for abuse, esketamine is only available through a restricted program. Patients must be monitored for at least two hours after each dose. Ketamine itself is still widely used in emergency departments and operating rooms as an anesthetic and pain reliever, particularly in situations where maintaining a patient’s breathing reflexes is important.
Risks of Regular Use
One of the more serious consequences of frequent ketamine use is bladder damage. Over 25% of people who use ketamine recreationally develop urinary symptoms, and around 20% of frequent users report symptoms resembling a bladder infection: urgency, pain, and frequent urination. The damage occurs because ketamine and its byproducts in urine directly irritate and inflame the bladder lining, eventually leading to scarring and reduced bladder capacity. This risk increases with dose and frequency of use.
The cardiovascular stimulation that makes ketamine look like an upper also carries real risks. In clinical settings, some patients show signs of reduced blood flow to the heart during ketamine administration, particularly those with pre-existing heart conditions. The temporary spike in blood pressure and heart rate is manageable in a monitored environment but unpredictable in recreational settings where doses are imprecise and no one is watching vital signs.
Repeated use can also lead to psychological dependence, cognitive impairment, and tolerance, meaning progressively larger doses are needed to achieve the same effect, which in turn accelerates bladder and cardiovascular damage.